Physician profile
Michael W Monohan
NPI 1942298054
$7,881.03
in general payments reported to CMS, 2019-2025
59 companies · $1,127 in 2025
The $1,127 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $955 · 2020: $881 · 2021: $1,517 · 2022: $1,331 · 2023: $1,112 · 2024: $958 · 2025: $1,127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,196.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,289.66 | 2019-2025 | |
| Pfizer INC. | $1,114.94 | 2019-2025 | |
| Glaxosmithkline, LLC. | $700.20 | 2019-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $623.39 | 2019-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $351.65 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $266.60 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.12 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $229.22 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $189.79 | 2019-2023 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $176.08 | 2019-2023 | Trulance, Xifaxan |
| Exact Sciences Corporation | $157.95 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $157.20 | 2019-2024 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $156.47 | 2020-2024 | Breztri, Airsupra |
| Abbott Laboratories | $145.39 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $133.18 | 2019-2022 |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $130.21 | 2023-2024 | Rexulti |
| Amarin Pharma, INC. | $128.36 | 2019-2021 | |
| Axonics, INC. | $117.32 | 2022 | |
| Corcept Therapeutics | $115.24 | 2021-2025 | Korlym |
| Merck Sharp & Dohme LLC | $111.12 | 2019-2025 | Gardasil 9, Rotateq, Vaxneuvance |
| Sanofi Pasteur INC. | $92.35 | 2019-2023 | |
| Allergan, INC. | $80.86 | 2019-2020 | |
| Antares Pharma, INC. | $69.92 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $65.51 | 2021-2025 | Keveyis, Recorlev |
| Horizon Therapeutics Plc | $64.88 | 2020-2023 | Krystexxa |
| Boston Scientific Corporation | $61.69 | 2021-2025 | Watchman Flx |
| Medtronic, INC. | $49.78 | 2024 | Intellis Adaptivestim |
| Corium, LLC | $45.65 | 2023 | Azstarys, Azstarys |
| Astellas Pharma US INC | $45.53 | 2019 | |
| Dexcom, INC. | $41.10 | 2024-2025 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $40.40 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $38.76 | 2023-2024 | Daybue |
| Ironshore Pharmaceuticals INC. | $38.27 | 2023 | Jornay Pm |
| Eisai INC. | $37.95 | 2020-2021 | |
| Mylan Specialty L.P. | $35.72 | 2020-2021 | |
| Gilead Sciences, INC. | $34.16 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $34.14 | 2021-2022 | |
| Organon LLC | $33.28 | 2021-2025 | Nexplanon |
| Alfasigma USA, INC. | $30.59 | 2020 | |
| Intercept Pharmaceuticals, INC. | $29.14 | 2021 | |
| Hologic Sales and Service, LLC | $27.97 | 2021-2022 | |
| Nevro Corp. | $27.72 | 2021 | |
| Insulet Corporation | $24.97 | 2024 | Omnipod |
| Grifols USA, LLC | $24.38 | 2021 | |
| Phathom Pharmaceuticals, INC. | $23.94 | 2024-2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $23.68 | 2022 | |
| Edwards Lifesciences Corporation | $21.96 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Becton, Dickinson and Company | $21.33 | 2021 | |
| Daiichi Sankyo INC. | $20.99 | 2019 | |
| Halozyme INC | $19.38 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $19.23 | 2022 | |
| Axsome Therapeutics, INC. | $18.28 | 2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $18.07 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.18 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.86 | 2019 | |
| Medtronic Vascular, INC. | $14.19 | 2019 | |
| Coopersurgical, INC. | $12.53 | 2021 | |
| Shire North American Group INC | $11.48 | 2019 | |
| Linus Health, INC. | $11.12 | 2024 | Core Cognitive Evaluation |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Monohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.